2.12. AML xenograft model

NOD‐SCID gamma (NSG) mice were purchased from Shanghai SLRC Laboratory Animal Center. Our animal study was approved by the Ethics Committee for Laboratory Animals of the First Affiliated Hospital, College of Medicine, Zhejiang University (Hangzhou, China), and was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were exposed to a 10/14‐h light–dark cycle, kept under normal room temperature, and fed standard pellet food and tap water.

For the MV4‐11‐NSG xenograft model (Biocytogen, Nanjing, China), 2 × 10⁶ MV4‐11 cells were injected into the NSG mice via the tail vein. After 7 days, cell engraftment was assessed by the expression of human CD45 by PBMCs of mice each week. Mice were randomly assigned to four groups according to the expression of human CD45. The four groups were treated as follows: 0.5% methylcellulose (MC, days 8–26, PO), 50 mg·kg⁻¹ abivertinib (days 8–26, PO), 75 mg·kg⁻¹ venetoclax (days 8–26, PO), or 50 mg·kg⁻¹ abivertinib and 75 mg·kg⁻¹ venetoclax (administered per the single‐agent groups). The mice were humanely sacrificed after observation of typical leukemic symptoms. PBMC, bone marrow, and spleen samples were harvested for flow cytometry analysis and IHC. Human CD45 antibody was used to identify engraftments.

The study methodologies conformed to the standards set by the Declaration of Helsinki.